Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T78656
|
||||
Former ID |
TTDR01194
|
||||
Target Name |
5-hydroxytryptamine 1F receptor
|
||||
Gene Name |
HTR1F
|
||||
Synonyms |
5-HT-1F; 5-HT1F receptor; Serotonin receptor; Serotonin receptor 1F; HTR1F
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Migraine [ICD9: 346; ICD10: G43] | ||||
Function |
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.
|
||||
BioChemical Class |
GPCR rhodopsin
|
||||
Target Validation |
T78656
|
||||
UniProt ID | |||||
Sequence |
MDFLNSSDQNLTSEELLNRMPSKILVSLTLSGLALMTTTINSLVIAAIIVTRKLHHPANY
LICSLAVTDFLVAVLVMPFSIVYIVRESWIMGQVVCDIWLSVDITCCTCSILHLSAIALD RYRAITDAVEYARKRTPKHAGIMITIVWIISVFISMPPLFWRHQGTSRDDECIIKHDHIV STIYSTFGAFYIPLALILILYYKIYRAAKTLYHKRQASRIAKEEVNGQVLLESGEKSTKS VSTSYVLEKSLSDPSTDFDKIHSTVRSLRSEFKHEKSWRRQKISGTRERKAATTLGLILG AFVICWLPFFVKELVVNVCDKCKISEEMSNFLAWLGYLNSLINPLIYTIFNEDFKKAFQK LVRCRC |
||||
Drugs and Mode of Action | |||||
Antagonist | 1-naphthylpiperazine | Drug Info | [534427] | ||
metergoline | Drug Info | [534427] | |||
Agonist | 2-methyl-5-HT | Drug Info | [534001] | ||
5-BODMT | Drug Info | [531404] | |||
5-CT | Drug Info | [534427] | |||
alpha-methyl-5-HT | Drug Info | [534001] | |||
BRL-15572 | Drug Info | [534475] | |||
dipropyl-5-CT | Drug Info | [534001] | |||
Lasmiditan | Drug Info | [532737] | |||
LY344864 | Drug Info | [534894] | |||
TFMPP | Drug Info | [534001] | |||
[125I]LSD | Drug Info | [526750] | |||
Modulator | LY-334370 | Drug Info | |||
Inhibitor | WAY-466 | Drug Info | [527381] | ||
Pathways | |||||
KEGG Pathway | cAMP signaling pathway | ||||
Neuroactive ligand-receptor interaction | |||||
Serotonergic synapse | |||||
PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
5HT1 type receptor mediated signaling pathway | |||||
Reactome | Serotonin receptors | ||||
G alpha (i) signalling events | |||||
WikiPathways | Serotonin HTR1 Group and FOS Pathway | ||||
Monoamine GPCRs | |||||
GPCRs, Class A Rhodopsin-like | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
GPCRs, Other | |||||
References | |||||
Ref 532737 | Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan. Neuropsychiatr Dis Treat. 2014 Mar 31;10:547-52. | ||||
Ref 534655 | G-protein activation at 5-HT1A receptors by the 5-ht1F ligand LY334370 in guinea-pig brain sections and recombinant cell lines. Br J Pharmacol. 1998 May;124(2):283-90. | ||||
Ref 526750 | Isolation of a mouse "5HT1E-like" serotonin receptor expressed predominantly in hippocampus. J Biol Chem. 1992 Oct 5;267(28):19761-4. | ||||
Ref 527381 | J Med Chem. 2005 Jan 27;48(2):353-6.Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists. | ||||
Ref 531404 | Toward selective drug development for the human 5-hydroxytryptamine 1E receptor: a comparison of 5-hydroxytryptamine 1E and 1F receptor structure-affinity relationships. J Pharmacol Exp Ther. 2011 Jun;337(3):860-7. | ||||
Ref 532737 | Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan. Neuropsychiatr Dis Treat. 2014 Mar 31;10:547-52. | ||||
Ref 534001 | Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):408-12. | ||||
Ref 534427 | Cloning and characterization of the guinea pig 5-HT1F receptor subtype: a comparison of the pharmacological profile to the human species homolog. Neuropharmacology. 1997 Apr-May;36(4-5):569-76. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.